02.10.2014 - Stocks of Esperion Therapeutics soared yesterday

The stock price of Esperion Therapeutics rose 38%, to levels around 33.50 dollars per share. Such a sharp increase in quotations of biotechnology company was caused by the unveiling of information regarding the interim results of samples of medicines for dealing with high cholesterol. Intermediate studies showed that the drug ETC-1002 is more effective than Ezetemibe from pharmaceutical giant Merck & Co. We recommend to include the company's shares in the long-term portfolio with growth potential up to 60-70% for the year.

RISK WARNING: Trading of complex financial products, such as Stocks, Futures, Foreign Exchange ("Forex"), Contracts for Difference ("CFDs"), Indices, Options, or other financial derivatives, on "margin" carries a high level of risk, and may not be suitable for all investors. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading these markets, and seek advice from an independent financial advisor if you have any questions or doubts. Please carefully read our full "Risk Disclosure" and "Risk Disclosures for Financial Instruments & Investment Services". FXFINPRO Capital is the trading name of PFX Financial Professionals Limited, a limited liability company formed under the laws of Cyprus, registered with the Registrar of Companies in Nicosia, Cyprus, under nr. HE 237840 and regulated by the Cyprus Securities and Exchange Commission with license number 193/13.